LTZ Therapeutics raises $38M unknown
LTZ Therapeutics raises $38M unknown announced on 2026-05-09.
LTZ Therapeutics raises $38M in a unknown round announced on 2026-05-09. LTZ Therapeutics describes itself as Advancing myeloid cell-based immunotherapy platform.
Lead investor data was not present in the structured funding record. The funding event is now linked to the company's Funded Work profile, where readers can review the capital signal alongside company and role data.
The source record for this funding event is https://devcuration.com/articles/ltz-therapeutics-raises-38m-to-advance-myeloid-cell-based-immunotherapy-platform. The structured record keeps this story tied to verified company and funding fields while additional editorial processing catches up.
Press
- LTZ Therapeutics Announces FDA Clearance of IND Application for LTZ-232 to Treat Advanced Metastatic Colorectal Cancer and Other Solid TumorsBusiness Wire · 7/7/2026
- LTZ bags $40 million as it sends first myeloid engager into clinicThe Pharma Letter · 4/25/2025
- LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune DiseasesBusiness Wire · 5/31/2023
- Former Genentech execs launch new immunotherapy biotech LTZ TherapeuticsBioWorld News · 5/2/2022
- LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301Business Wire · 2/24/2025
About the Company
Advancing myeloid cell-based immunotherapy platform
LTZ Therapeutics